MedTrace Logo

V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

NCT00109343 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1027

Last updated 2017-04-12

Study results available
· View outcomes & findings →

Summary

The study is being conducted to demonstrate that V221 may be administered concomitantly with pneumococcal conjugate vaccine without impairing the safety or immunogenicity of measles, mumps, rubella, varicella, or the 7 serotypes of S. pneumoniae.

Conditions

Interventions

BIOLOGICAL

Comparator: ProQuad™ (V221)

0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)

BIOLOGICAL

Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)

0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
15 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2007-09-30
Completion
2007-09-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00109343 on ClinicalTrials.gov